EMA Application withdrawn: IXinity (trenonacog alfa;trenonacog alfa) — Cangene Europe Limited

View source ↗

Summary

The EMA withdrawn the application for IXinity (trenonacog alfa) by Cangene Europe Limited in the therapeutic area of Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IXinity (trenonacog alfa)

Snippet

Status: Application withdrawn. Therapeutic area: Hemophilia B. MAH: Cangene Europe Limited. Decision date: 28/06/2013